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This longitudinal prospective study shows that antibodies to the N-terminal block 2 region of the Plasmodium
falciparum merozoite surface protein 1 (MSP-1) are associated with protection against clinical malaria in an
area of stable but seasonal malaria transmission of Ghana. Antibodies to the block 2 region of MSP-1 were
measured in a cohort of 280 children before the beginning of the major malaria transmission season. The
cohort was then actively monitored for malaria, clinically and parasitologically, over a period of 17 months.
Evidence is presented for an association between antibody responses to block 2 and a significantly reduced risk
of subsequent clinical malaria. Furthermore, statistical survival analysis provides new information on the
duration of the effect over time. The results support a conclusion that the block 2 region of MSP-1 is a target
of protective immunity against P. falciparum and, thus, a promising new candidate for the development of a
malaria vaccine.
The asexual erythrocytic stages of Plasmodium falciparum
infection are responsible for all clinical manifestations of ma-
laria, and antigens on the asexual merozoite stage are believed
to be important in the development of protective immunity to
the disease. One such antigen, the P. falciparum merozoite
surface protein 1 (Pf MSP-1), is the precursor of the major
antigenic complex on the surface of blood merozoites (16, 20,
25). Importantly, since MSP-1 is also expressed in liver schi-
zonts (37), immunity to MSP-1 has the potential to control
early liver-derived merozoites before the infection can
progress to the blood phase and the disease.
The MSP-1 gene of P. falciparum is divided into 17 distinct
blocks that encode conserved, dimorphic or polymorphic re-
gions of the protein (19, 26, 38). MSP-1 alleles belong to one or
the other of two families based on the dimorphic sequences
and named after the MAD20 and Wellcome isolates (38). The
block 2 region, located within the N-terminal half of MSP-1, is
more polymorphic, with over 50 different sequence variants
identified. However, all block 2 sequences belong to one or
another of only three main sequence types represented by
prototypic variants originally identified in the K1, MAD20, and
RO33 isolates (9, 21, 38). Variants within the K1-like and
MAD20-like types of block 2 differ in tri- or hexapeptide re-
peats (21, 26, 38), whereas block 2 of the RO33 type is a
nonrepetitive sequence which varies little between isolates (9,
26) (Fig. 1). Importantly, the main sequence types are recog-
nized as three major block 2 serotypes by human antibodies
produced in response to natural P. falciparum infections (6–8).
MSP-1 has been the focus of many epidemiological studies
on human immune responses to natural malaria infections
(22). Antibodies to the conserved C-terminal MSP-119 are
found in the majority of malaria-exposed individuals (14, 31),
and the presence of such antibodies has been correlated with
protection from clinical symptoms of malaria in some, though
not all, studies (12, 15, 31). The roles in human malaria im-
munity of responses induced by other regions of this large
protein remain almost unknown. Early studies suggested that
antibodies to the polymorphic and/or dimorphic sequences
located in the N-terminal half of MSP-1 are important (10, 17,
27, 41). Gabonese patients who had cleared infections had
higher levels of immunoglobulin G (IgG) against an N-termi-
nal fragment of MSP-1 than patients who had persistent infec-
tions (10). Furthermore, in another study low and short-lived
antibody responses to N-terminal regions of MSP-1 correlated
with a higher risk of subsequent reinfection (41). More re-
cently, a new approach combining population genetics with an
immunoepidemiological prospective cohort study has identi-
fied specifically the block 2 region of Pf MSP-1 as a major
target of human immunity against P. falciparum malaria (11).
Since block 2 of Pf MSP-1 has no homologue in most animal
species of malaria parasites, there is no convenient animal
model to validate this new candidate for vaccine development.
Thus, to progress further, it is essential to extend immunoepi-
demiological studies in the natural hosts, i.e., human popula-
tions exposed to P. falciparum malaria.
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This prospective study is a part of a program to characterize
patterns of naturally acquired immune responses to block 2
and other defined proteins of P. falciparum in ethnically varied
people exposed to variable levels of malaria infections. Here,
block 2-specific antibodies were analyzed in children from an
area of seasonal malaria transmission in Dodowa, Ghana, be-
fore malaria transmission began. We report significant associ-
ations between the presence of IgG (particularly IgG3) to two
of the three main types of the block 2 region and subsequent
protection from clinical malaria episodes, thus strengthening
evidence obtained earlier in The Gambia (11). Furthermore,
new information is presented here on the duration of this
protection.
MATERIALS AND METHODS
Study area. The study was conducted in the town of Dodowa (population circa
6,500), 50 km northeast of Accra, Ghana. The area is defined as one of hyper-
endemicity with seasonal malaria transmission. There are two rainy seasons, a
major season from May to August and a minor one between October and
November. A relatively dry period follows the second rains and lasts from
December to April. Malaria transmission is classified as perennial and stable but
is highest during or immediately after the major and minor rainy seasons and
lowest during the dry season (12). It is estimated that each individual in Dodowa
is exposed to approximately 20 infective bites per year, and 98% of malaria
infections are due to P. falciparum (1).
Study population and clinical surveillance. A cohort of 280 children, typed
negative for sickle cell trait, was recruited to the study in April 1994. The children
were 3 to 15 years of age; 54% were male and 46% were female. Each age group
within the cohort included between 12 and 34 children. The study was approved
by the Ghanaian Ministry of Health, and informed parental consent was obtained
for each child after an explanation of all procedures involved. The study started
in April 1994 and was completed in August 1995. Blood slides were obtained
from all children once a month to determine the point prevalence of parasitemia.
Throughout this 17-month period, field assistants resident in Dodowa actively
monitored the cohort for clinical symptoms and blood parasitemia. During
weekly visits to each child, information regarding the child’s health status in the
previous week was recorded on a standard questionnaire form, and axillary
temperature was measured by using a digital thermometer. Blood slides were
taken from all children with temperatures of 37.5°C and also from children
complaining of symptoms suggestive of malaria, and samples were checked for
parasitemia. Parents were instructed to bring sick children to the field assistants
also outside the scheduled weekly visits for recording of temperature and blood
parasitemia determination by finger prick. Any child with detectable parasitemia
and fever was immediately treated with chloroquine. In analyses of the clinical
data, individuals were considered to have had clinical malaria if (i) they reported
fever and/or had a measured temperature higher than 37.5°C and (ii) they had
parasitemia of 5,000 parasites per l. The parasite cutoff level of 5,000 para-
sites/ml was based on morbidity and gave a sensitivity and specificity of 90% (40).
In children with fever but parasitemia below this threshold, it is uncertain
whether the symptoms were due to malaria (36). Data on antibody responses to
block 2 and other regions of MSP-1 are based on analyses of plasma samples
obtained from 280 children for whom clinical and parasitological data were
available for the duration of the 17-month follow-up period.
Plasma samples. Venous blood samples were obtained from the cohort indi-
viduals on two occasions. All 280 children donated samples in April 1994, just
before the onset of the major malaria transmission season. Second samples from
266 of the donors were collected in November 1994, after the malaria transmis-
sion season. Each sample was drawn aseptically into heparinized Vacutainer
tubes (Becton Dickinson, Rutherford, N.J.). Plasmas were separated under ster-
ile conditions and stored at 20°C. Negative control plasma samples were ob-
tained from 34 healthy European adults who were malaria naïve. Positive con-
trols were individual plasmas and a pool of plasmas from adult African donors,
selected for high antibody reactivity to MSP-1 antigens (7, 8).
Recombinant antigens. A panel of recombinant proteins derived from MSP-1,
including full-length block 2 sequences of culture-adapted (3D7, Palo Alto,
MAD20, Wellcome, and RO33) and field isolates (DWK1#1, DWK1#2,
DWMAD20, and DWRO33) and a block 1 (MAD20 variant) protein, were
immunologically validated earlier (8). These antigens all induce animal antibod-
ies that recognize parasite-produced MSP-1 with specificities as appropriate for
distinct block 2 types expressed by a range of P. falciparum isolates (8). Gluta-
thione S- transferase (GST) fusion proteins containing repeat-only block 2 se-
quences from the 3D7, Palo Alto, MAD20, and Wellcome isolates and also
proteins containing only the K1-type and MAD20-type flanking sequences have
been described elsewhere (29). Sequences of the block 2 antigens are shown in
Fig. 1. A protein corresponding to the C-terminal MSP-119 was described and
immunologically evaluated earlier (5). All antigens were expressed in Escherichia
coli as soluble proteins fused to the C terminus of GST of Schistosoma japonicum
by using the pGEX-2T vector and purified by published methods (35). Control
GST protein was prepared from E. coli harboring pGEX-2T alone.
FIG. 1. Schematic diagram of MSP-1 block 2 sequences of all recombinant antigens are shown in single amino acid code. Asterisks indicate stop
codons.
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ELISA. Human plasma samples were tested by enzyme-linked immunosorbent
assay (ELISA) for the presence of IgG antibodies able to recognize the recom-
binant MSP-1 antigens. Wells of 96-well plates (Immulon 4; Dynatech) were
coated with 50 ng of recombinant antigens in 100 l of coating buffer (15 mM
Na2CO3, 35 mM NaHCO3 [pH 9.3]) overnight at 4°C. The wells were washed
three times in washing buffer (0.05% Tween 20 in phosphate-buffered saline).
Unoccupied protein binding sites were blocked with 200 l per well of blocking
buffer (1% [wt/vol] skim milk powder in washing buffer) for 5 h at room tem-
perature and washed again three times. Human plasma diluted 1:500 in the
blocking buffer (100 l per well) was added to duplicate antigen-coated wells and
incubated overnight at 4°C. After three washes, the wells were incubated for 3 h
at room temperature with 100 l per well of horseradish peroxidase-conjugated
rabbit anti-human IgG (1:5,000) (Dako Ltd., High Wycombe, United Kingdom).
Plates were washed three times before incubating for 15 min at room tempera-
ture with 100 l of substrate (0.1 mg of o-phenylenediamine [Sigma] per ml,
0.012% H2O2) in development buffer (24.5 mM citric acid monohydrate and 52
mM Na2HPO4, pH 5.0). The reaction was stopped by the addition of 25 l of 2
M H2SO4, and the optical density at 492 nm (OD492) was measured. Corrected
OD values for each plasma sample were calculated by subtracting the mean OD
value of wells containing the control GST protein alone from the mean OD value
obtained with each test MSP-1 antigen. For IgG1 and IgG3 subclass-specific
ELISAs, plasma samples were diluted 1:250 in blocking buffer and detected as
above by using polyclonal sheep antibodies specific for human IgG1 (1:1,000) or
IgG3 (1:1,500) (The Binding Site, Birmingham, United Kingdom).
Cutoff values, at which the binding of antibody from malaria-exposed individ-
uals was regarded as significantly above background, were calculated as the mean
plus three standard deviations of OD readings obtained with sera from 34
Scottish blood donors with no history of exposure to malaria. For total IgG, the
cutoff OD value for each antigen was as follows: MAD20 block 1, 0.078; 3D7
block 2, 0.206; 3D7 repeats, 0.242; Palo Alto block 2, 0.179; Palo Alto repeats,
0.276; DWK1 block 2 #1, 0.083; DWK1 block 2 #2, 0.064; K1 block 2 flank,
0.267; MAD20 block 2, 0.023; MAD20 repeats, 0.175; Wellcome block 2, 0.208;
Wellcome repeats, 0.283; DW MAD20 block 2, 0.069; MAD20 block 2 flank,
0.200; RO33 block 2, 0.063; DW RO33 block 2, 0.061; MSP-119, 0.073. For
IgG1-specific ELISA, the cutoff OD value for each antigen was as follows: 3D7
block 2, 0.029; Palo Alto block 2, 0.015; DWK1 block 2 #1, 0.017; DWK1 block
2 #2, 0.015; MAD20 block 2, 0.015; Wellcome block 2, 0.013; DW MAD20 block
2, 0.017; RO33 block 2, 0.017; DW RO33 block 2, 0.020; MSP-119, 0.020. For
IgG3-specific ELISA, the cutoff OD value for each antigen was as follows: 3D7
block 2, 0.052; Palo Alto block 2, 0.027; DWK1 block 2 #1, 0.023; DWK1 block
2 #2, 0.023; MAD20 block 2, 0.016; Wellcome block 2, 0.017; DW MAD20 block
2, 0.021; RO33 block 2, 0.020; DW RO33 block 2, 0.019; MSP-119, 0.013.
Statistical analysis. Statistical analysis was done with the SPSS software pack-
age (SPSS Inc., Chicago, Ill.) and the EpiInfo 2000 software package (http:
//www.cdc.gov/epiinfo/). The 2 test or Fisher’s exact test was used to compare
the proportions of children with and without malaria (unprotected and pro-
tected) in groups of antibody-positive and antibody-negative individuals and to
compare the frequencies of antibody positivity in pre- and postmalaria season
samples. To assess the effects of age on associations between antibody positivity
(or antibody levels, as measured in absorbance units) and malaria outcome, data
were also analyzed by multivariate (logistic regression) analysis, in which age was
accounted for as a confounding variable. Survival analysis, according to the Cox
proportional hazard model, was used to compare data on first clinical malaria
episodes in children for each antigen, with age included in the model as a
confounding variable. Differences were considered statistically significant if
P was 0.05.
RESULTS
Malaria in the study cohort. All except two children in the
cohort were blood film positive for P. falciparum at one or
more of the monthly screenings done to determine parasite
point prevalence (12). Interestingly, only some of these infec-
tions were symptomatic. The incidence of malaria varied con-
siderably over the year, peaking in August 1994 and again in
July 1995 and reaching the lowest levels in April 1994 and
February 1995 (12). During the 17-month period of surveil-
lance, 108 of 280 (38.6%) children had at least one clinical
episode of malaria, and these children were considered to be
susceptible to malaria. A total of 172 of 280 (61.4%) children
did not have complaints of fevers or measured febrile temper-
atures in the presence of asexual parasitemia (5,000 para-
sites/ml) at any of the weekly screenings, and these children
were considered to be protected from clinical malaria. Suscep-
tible children tended to be younger (median age, 6 years;
range, 3 to 15 years) than the protected children (median age,
9 years; range, 3 to 15 years) (P  0.00001).
Antibody responses to block 2 and other regions of MSP-1
depend on exposure and age. Seropositivity frequencies of
children with antibodies to 11 antigens derived from MSP-1
were measured by using plasma samples taken in April before
the start of seasonal malaria transmission and after the season
in November 1994. In the preseason samples from 280 chil-
dren, the most commonly recognized antigen was MSP-119
(56%), followed by various block 2 constructs (between 2.5 to
22%), while only 1.4% of the samples contained detectable
levels of antibodies to the block 1 antigen (Fig. 2). After the
transmission season, the frequencies of seropositivity moder-
ately increased, with 62% of children having detectable anti-
bodies to MSP-119, followed by 13 to 32% with antibodies to
block 2 antigens, and 3.8% antibody positive for block 1. These
seasonal increases were statistically significant for all antigens
tested, except for block 1 and two block 2 variants (DWK1#1
and DWRO33) (Fig. 2A).
The overall prevalence of antibody positivity to any block 2
antigen tested was age dependent, increasing from 19.4% in
the group of 3- to 5-year-olds, 45% in the group of 6- to
9-year-olds, to 58.3% in the group of 10- to 15-year-olds. In
comparison, little increase in antibody prevalence with age was
seen to MSP-119, (51.1, 56, and 59.4% in the three age groups,
respectively).
Antibodies to block 2 and protection from malaria. The
relative risks of clinical malaria were compared over a 17-
month period between groups of children with or without an-
tibodies to different regions of MSP-1 at the start of the period.
Lower frequencies of clinical malaria were seen among chil-
dren who had IgG antibodies to block 2 (Table 1, group A).
For most block 2 antigens, there were statistically significant
associations between the presence of detectable IgG and a
lowered relative risk of clinical malaria episodes during the
follow-up period (Table 1, group A, and Table 2). Antibodies
to most full-length antigens from the two common block 2
types, namely the K1- and MAD20-like types, were signifi-
cantly associated with protection in this cohort, as shown by the
relative risk values for IgG-positive children, specific for each
antigen, which were significantly less than 1.0 (Table 1). Anti-
bodies to two antigens (3D7 and DWK1#2), for which there
was no statistically significant association, still showed the same
trend. This association was also statistically significant for an-
tibodies to the repeat-only antigens of the MAD20 block 2
type. For antibodies to the repeat-only antigens of the K1 type,
a trend toward reduced risk was apparent, although this was
not statistically significant (Table 1). The association of anti-
bodies to block 2 with a reduced risk of clinical malaria was
also statistically highly significant when the data were analyzed
for children who were antibody positive for any block 2 variant,
versus those without antibodies to any variant tested (P 
0.009) (Table 1). Children with antibodies to both the MAD20-
like and K1-like types also had a significantly lower incidence
of clinical malaria episodes (P  0.0038) (Table 1). All signif-
6494 CAVANAGH ET AL. INFECT. IMMUN.
icant associations between antibody positivity to any block 2
antigen that had a P value of  0.01 remained statistically
significant (P  0.05), when age was accounted for as a con-
founding variable by multivariate logistic regression analysis
(data not shown). When antibody levels (i.e., corrected absor-
bance values) against the block 2 antigens (rather than posi-
tive-negative scoring of antibody reactivity) were analyzed by
multinomial logistic regression analysis for associations with
reduced incidence of malaria, highly significant P values (0.01
or less) were obtained for all flock 2 antigens tested. This
FIG. 2. Frequencies and isotype biases of IgG antibodies to different regions of MSP-1. (A) Frequencies of seropositive individuals in the
cohort before malaria transmission season (April 1994; n  280) and after the season (November 1994; n  266). Percentages of antibody-positive
individuals for each full-length Block 2 antigen, Block 1, and MSP-119 are shown as bars. Asterisks indicate pairs of frequencies that significantly
increased between the two samplings (P  0.05). (B) Comparisons between IgG1 and IgG3 subclasses to Block 2 and MSP-119. Each point
represents levels of antigen-specific subclasses in the April sample from one individual.
VOL. 72, 2004 PROTECTIVE HUMAN ANTIBODIES TO MSP-1 BLOCK 2 6495
TABLE 1. Incidence of clinical malaria in antibody-positive and -negative groups of children to particular recombinant antigenic fragments
of MSP-1
Antibody group and
antigena
Proportion (%) of clinical malaria (no. of positive
samples/total no. of samples) among:b RR (95% CI)c P valued
IgG-positive children IgG-negative children
Group A
K1 Block 2 type
3D7 full 39.5 (15/38) 38.4 (93/242) 1.03 (0.67–1.57) 0.902
3D7 rpts 27.8 (10/36) 40.2 (98/244) 0.69 (0.40–1.20) 0.154
Palo Alto full 27.1 (19/70) 42.4 (89/210) 0.64 (0.42–0.97) 0.023*
Palo alto rpts 15.4 (2/13) 39.7 (106/267) 0.39 (0.11–1.40) 0.079
DWK1#1 full 26.7 (16/60) 41.8 (92/220) 0.64 (0.41–1.00) 0.033*
DWK1#2 full 28.9 (11/38) 40.1 (97/242) 0.72 (0.43–1.22) 0.19
K1 flanking 28.6 (6/21) 39.4 (102/259) 0.73 (0.36–1.45) 0.328
MAD20 Block 2 type
MAD20 full 21.1 (12/57) 43.0 (96/223) 0.49 (0.29–0.83) 0.002**
MAD20 rpts 14.3 (3/21) 40.5 (105/259) 0.35 (0.12–1.02) 0.017*
Wellcome full 12.9 (4/31) 41.8 (104/249) 0.31 (0.12–0.78) 0.002**
Wellcome rpts 13.3 (2/15) 40.0 (106/265) 0.33 (0.09–1.22) 0.039*
DWMAD20 full 11.1 (3/27) 41.5 (105/253) 0.27 (0.09–0.79) 0.002**
MAD20 flanking 14.3 (1/7) 39.2 (107/273) 0.36 (0.06–2.25) 0.181
RO33 Block 2 type
RO33 full 31.3 (5/16) 39.0 (103/264) 0.80 (0.38–1.68) 0.536
DWRO33 full 38.2 (13/34) 38.6 (95/246) 0.99 (0.63–1.56) 0.966
K1 plus MAD20 type 16.7 (6/36) 41.8 (102/244) 0.40 (0.19–0.84) 0.0038**
Any Block 2 29.6 (34/115) 44.8 (74/165) 0.66 (0.47–0.92) 0.009**
MSP119 37.8 (59/156) 39.5 (49/124) 0.96 (0.71–1.29) 0.772
MAD20 Block 1 25 (1/4) 38.8 (107/276) 0.64 (0.12–3.54) 0.574
Group B
K1 Block 2 type
3D7 full 6.25 (1/16) 40.5 (107/264) 0.15 (0.02–1.03) 0.006**
Palo Alto full 30.0 (15/50) 40.4 (93/230) 0.74 (0.47–1.17) 0.169
DWK1#1 full 30.0 (6/26) 40.1 (102/254) 0.57 (0.28–1.18) 0.088
DWK1#2 full 21.4 (3/11) 39.5 (105/266) 0.54 (0.20–1.50) 0.176
MAD20 Block 2 type
MAD20 full 25.0 (8/32) 40.3 (100/248) 0.62 (0.33–1.15) 0.094
Wellcome full 26.7 (12/45) 40.9 (96/235) 0.65 (0.39–1.09) 0.073
DWMAD20 full 38.5 (5/13) 38.6 (103/267) 1.00 (0.49–2.02) 0.993
RO33 Block 2 type
RO33 full 35.3 (6/17) 38.8 (102/161) 0.91 (0.47–1.76) 0.775
DWRO33 full 38.2 (13/34) 38.6 (95/246) 0.99 (0.63–1.56) 0.966
Any Block 2 32.2 (38/118) 43.2 (70/162) 0.75 (0.54–1.02) 0.06
MSP119 39 (69/108) 37.9 (39/103) 1.03 (0.76–1.40) 0.853
Group C
K1 Block 2 type
3D7 full 30.2 (13/43) 40.1 (95/237) 0.75 (0.47–1.22) 0.223
Palo Alto full 31.3 (21/67) 40.8 (87/213) 0.77 (0.52–1.13) 0.163
DWK1#1 full 26.8 (19/71) 42.6 (89/209) 0.63 (0.41–0.95) 0.018*
DWK1#2 full 32.7 (17/52) 39.9 (91/228) 0.82 (0.54–1.25) 0.334
MAD20 Block 2 type
MAD20 full 20.0 (13/65) 44.2 (95/215) 0.45 (0.27–0.75) 0.0004***
Wellcome full 28.8 (21/73) 42.0 (87/207) 0.68 (0.46–1.02) 0.045*
DWMAD20 full 22.2 (8/36) 41 (100/244) 0.54 (0.29–1.02) 0.031*
RO33 Block 2 type
RO33 full 41.7 (20/48) 37.9 (88/232) 1.11 (0.76–1.61) 0.598
DWRO33 full 36.4 (16/44) 38.9 (92/236) 0.93 (0.61–1.42) 0.744
Any Block 2 29.5 (41/139) 47.5 (67/141) 0.62 (0.46–0.85) 0.002**
MSP119 30.6 (33/108) 39.3 (75/191) 0.78 (0.56–1.09) 0.133
a Group A, IgG-positive and IgG-negative individuals; Group B, IgG1-positive and IgG1-negative individuals; and Group C, IgG3-positive and IgG3-negative
individuals.
b Percentages apply to children with antibodies to regions of MSP-1 at the start of the study period who subsequently contracted malaria in the follow-up period.
c The calculated relative risk (RR) of malaria in the antibody positive groups is shown with 95% confidence intervals (CI).
d *, P  0.05; **, P  0.01; ***, P  0.001. All protective associations with P values below 0.01 remained statistically significant when analyzed by multiple logistic
regression, after adjusting for age as a confounding variable in the analysis.
6496 CAVANAGH ET AL. INFECT. IMMUN.
finding indicates that differences in the absolute levels of an-
tibody against flock 2, as measured by absorbance values in
ELISAs, are important in terms of protective effect.
No statistically significant associations were found between
antibodies to the flanking sequences of either the K1 or the
MAD20 block 2 types and reduced risk of malaria (Table 1).
This is in agreement with results from another cohort from The
Gambia (29). Antibodies to the conserved block 1 and MSP-
119 regions, or to the nonpolymorphic RO33 block 2 type, were
not associated with a reduced risk of subsequent malaria epi-
sodes in this cohort (Table 1).
The P values shown in Table 1 were calculated without
corrective adjustments for multiple comparisons, mainly be-
cause the multiple facets of the analyses introduce consider-
able uncertainty about the number of independent tests per-
formed or implied. Here the testing is not of independent null
hypotheses but related ones; block 2 antigens within each block
2 type share epitopes and amino acid sequence homologies,
and some tested block 2 antigens (e.g., block 2 flanking anti-
gens) are, in fact, subsections of other, longer antigens in the
same assays. Following the suggestions of Rothman (32) and
Perneger (28), we prefer to show the data in their unadjusted
form to allow value judgments to be made of the significance of
the reduction in malaria incidence for each antibody to each
antigen in terms of its biological plausibility.
Survival analysis of time to clinical malaria. The data were
subjected to survival analysis by using Cox’s proportional haz-
ards regression model, including age as a covariate in the
analysis to estimate, as another index of protection, the relative
risk of malaria episodes subsequent to the determination of
antibodies to specific antigens. This analysis revealed clear
associations between the presence of IgG to the block 2 region
and the time free from clinical malaria (Table 2 and Fig. 3).
Differences in malaria-free survival times between antibody-
positive versus antibody-negative groups were particularly
clear during the first transmission season following the initial
testing for antibodies in April 1994 (Fig. 3A and B, day 0 to day
250). The protective association of antibodies detected in these
individuals appeared to be relatively short-lived, as differences
in survival rates were negligible beyond the end of the first
transmission season (Fig. 3A to C, day 400 onwards). However,
this still indicates protective associations between possession of
antibodies to block 2 and a reduced risk of malaria for at least
250 days. There was no significant association between anti-
bodies to either the RO33 block 2 type or MSP-119 and this
index of protection, although there was a somewhat lower
incidence of malaria in the group with antibodies to MSP-119
in the first transmission season (Fig. 3D).
Children with antibodies to any block 2 antigen had a sig-
nificantly lowered risk of clinical malaria over time (Fig. 3C).
Recategorization of the children as positive or negative for
clinical malaria episodes during shorter periods of surveillance
(between 1 and 11 months following the first blood sampling)
did not change the associations between anti-block 2 antibody
positivity and clinical protection (data not shown). Depending
on the block 2 antigen, the relative risk (expressed as a hazard
ratio in Cox proportional hazards model) of a malaria episode
varied from 0.11 to 0.858 (Table 2). For the K1 and MAD20
block 2 types, this association was statistically significant for
four of the antigens tested (Table 2, Palo Alto, DWK1#1,
MAD20, and Wellcome), and the weaker associations in both
these two types still showed the same trend (Table 2, all other
K1- and MAD20-type antigens). No such association was seen
with antibodies to the conserved antigens (block 1 and MSP-
119) or to the RO33 block 2 type (Table 2). In summary, these
data support the hypothesis that antibodies to the K1 and
MAD20 types of block 2 contribute significantly to protection
against malaria in this cohort.
IgG subclass specificities of anti-MSP-1 antibody responses.
Seeking an explanation for the relatively fast decline of the
protective effect of anti-block 2 antibodies, IgG subclasses of
antibodies to various MSP-1 antigens were determined in the
cohort by using IgG1 and IgG3 subclass-specific reagents (6).
All 280 plasma samples from April 1994 were tested against all
full-length block 2 antigens and against MSP-119. Other block
2 antigens contained within the sequences of the full-length
antigens (i.e., repeat-only and flanking antigens) were not an-
alyzed due to the very limited volumes of serum available.
Limited serum volumes precluded subclass analysis of the No-
vember samples from the same cohort. The responses to MSP-
119 were predominantly of the IgG1 subclass, with a few sera
containing IgG3 alone or both IgG1 and IgG3 (Fig. 2B). In
marked contrast, antibodies to all block 2 antigens were re-
stricted predominantly to the IgG3 subclass, with only some
sera also showing weak IgG1 reactivities (Fig. 2B). Conse-
quently, the associations between antibodies to block 2 and
reduced risks of malaria were statistically significant for most
antigens when the IgG3 subclass was measured but not when
IgG1 was assessed (Table 1, groups B and C).
Specificities of antibody responses to MSP-1 block 2 are not
fixed. Paired plasma samples collected before and after ma-
TABLE 2. Survival analysis of time to clinical malariaa
Antigen
Regression
coefficient
(B)
Hazard
ratio 95% CI P value
K1 Block 2 type
3D7 Block 2 1.035 0.355 (0.117–1.075) 0.067
3D7 repeats 0.448 0.639 (0.246–1.659) 0.358
Palo Alto Block 2 1.223 0.294 (0.088–0.982) 0.047*
Palo Alto repeats 0.939 0.391 (0.055–2.801) 0.350
DWK1#1 Block 2 1.060 0.347 (0.121–0.989) 0.048*
DWK1#2 Block 2 1.580 0.206 (0.033–1.284) 0.091
K1 flanking 0.844 0.430 (0.091–2.031) 0.287
MAD20 Block 2 type
MAD20 Block 2 1.847 0.158 (0.032–0.779) 0.023*
MAD20 repeats 0.858 0.424 (0.091–1.985) 0.276
Wellcome Block 2 2.209 0.110 (0.014–0.878) 0.037*
Wellcome repeats 1.210 0.298 (0.047–1.873) 0.197
DWMAD20 Block 2 1.364 0.256 (0.064–1.023) 0.054
MAD20 type
flanking
1.770 0.170 (0.010–2.927) 0.223
RO33 Block 2 type
RO33 Block 2 0.432 0.649 (0.184–2.283) 0.500
DWRO33 Block 2 0.153 0.858 (0.284–2.590) 0.786
Any Block 2 0.453 0.636 (0.351–1.152) 0.135
Block 1 0.419 0.658 (0.107–4.047) 0.651
MSP-119 0.049 1.050 (0.809–1.362) 0.715
a Survival analysis calculated by using Cox proportional hazards model of the
times to clinical malaria episodes in the cohort, for each antigen tested. Age was
included in each model as a confounding variable as follows: coefficient (B),
0.703; hazard ratio, 0.495; 95% confidence interval (CI), (0.354–0.693); P
value,  0.0001***.
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laria transmission (April and November 1994) from 236 indi-
viduals were tested for the presence of antibodies to block 2
antigens, and the results were then analyzed for changes or
similarities in antibody specificities for different variants and/or
types of block 2 antigens. Among initially antibody-negative
children (210 to 265 individuals, depending on the antigen), 18
to 43 became antibody positive for one or another block 2
antigen between April and November. Among those children
who were initially block 2 antibody positive (between 16 and
70, depending on the antigen), between 3 to 16 became anti-
body negative for any one block 2 antigen by November. Some
antibody-positive individuals were seen to acquire additional
block 2 antibody specificities that had not been present in the
earlier sample (Fig. 4A and B), and some individuals who
FIG. 3. Kaplan-Meier plots of the cumulative incidence of first malaria episodes between antibody-positive and antibody-negative groups of
children over the 17-month follow-up period. Proportions of children who remained malaria free in the antibody-positive and antibody-negative
groups are shown as solid lines and dashed lines, respectively. Censored cases in the follow-up are shown by open symbols. The effects of IgG
antibodies to different antigens are analyzed in separate panels.
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acquired new block 2 antibody specificities between April and
November also became antibody negative for the block 2 type
for which they had been positive in April (Fig. 4A). The chang-
ing patterns of acquisition and/or loss of block 2 antibody
specificities by a significant number of children indicates that
the responses seen are possibly a result of new infections and
generally do not remain fixed in this cohort.
DISCUSSION
One aim of this study was to compare the apparent immu-
nogenicity of the polymorphic block 2 and two conserved re-
gions of MSP-1 in children living under conditions of stable but
seasonal malaria transmission in Dodowa. Between 5 and 32%
of the children had antibodies to one or another block 2 anti-
FIG. 4. Changes in the specificity of Block 2 antibodies. Typical patterns of changes in Block 2 specificity with time are illustrated by antibody
reactivities of pairs of serum samples taken from donors 329 and 41. Antibody reactivity is expressed as the OD492, comparing preseason (April
1994) and postseason (November 1994) samples from each donor side by side. MSP-1 antigens are shaded by type, as shown in the key. Panel A
shows a changeover from a narrow MAD20-type specificity to K1-type specificities. Panel B shows boosts of antibody responses to K1 and MAD20
types and also the acquisition of antibodies against the RO33 type.
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gen, with a total of 41% of the cohort positive for at least one
block 2 antigen before malaria transmission season in April,
increasing to 53% positive after the season. These frequencies
are in broad agreement with results of earlier studies carried in
other populations from areas of different malaria endemicity
(41). Anti-block 2 antibody frequencies tend to be lower than
the frequency of antibodies to the conserved MSP-119 (55 to
60%). However, exposure to any one type of block 2 antigen is
less frequent than to conserved domains like MSP-119, and,
thus, the probability of a sustained primary or memory anti-
body response to a parasite expressing the same type of block
2 antigen is likely to be lower. Exposure and, thus, responses to
internal polymorphic repetitive sequences from individual
block 2 variants are likely to be lower still, as illustrated here by
the low seroprevalence of antibodies to the repeat-only block 2
antigens (5 to 13%). An age-dependent increase in antibody
prevalence to block 2, similar to the age-dependent prevalence
of antibodies to several other merozoite antigens, probably
reflects the number of past malaria infections experienced by
each child (2, 34). This contrasts with the small age-related rise
in antibody prevalence to MSP-119. These results are in agree-
ment with earlier assays performed on this same cohort (12)
and probably reflect the fact that MSP-119 is a nonpolymorphic
portion of MSP-1 to which all children in the cohort had been
previously exposed. However, at 56%, the prevalence of anti-
bodies to MSP-119 detected in this study is higher than the
frequency of 31% reported with the same set of plasma sam-
ples and the same recombinant antigen (5, 14). The sensitivity
of the assay used here may be higher than in the earlier study
that used a higher plasma dilution (1:1,000 compared to 1:500
here). The frequency of MSP-119 antibodies seen in this work
is closer to that observed in The Gambia (11), in Sudan (7),
and in Kenya (4). Antibody to MSP-1 block 1 antigen was
detected in only a few individuals (four in April and nine in
November), thus extending earlier observations of low anti-
body prevalence to block 1 in other cohorts in The Gambia and
Sudan (7, 11) and of others in Senegal (where a synthetic
peptide containing part of the block 1 sequence was used [24]).
These findings indicate that although block 1 is conserved, it
may be a poor immunogen and that antibody responses to
block 1 antigen are not boosted by natural P. falciparum infec-
tions.
Antibodies to the full-length block 2 antigens were associ-
ated with a statistically significant reduced risk of clinical ma-
laria episodes over a 17-month follow-up period. Survival anal-
ysis of this effect over time shows that the final outcome
reflects a significant prolongation of time without malaria over
the first malaria season (some 250 days or longer). This indi-
cates a relatively short persistence of effective antibodies, their
production, or both. The interpretation is in keeping with the
finding that serum IgG to block 2 antigens in these Ghanaian
children is predominantly of the IgG3 subclass. This further
extends recent findings in three other East African populations
(6), showing a strong IgG3 bias to be a general feature of
human response to block 2 (in contrast to IgG1-biased re-
sponses to MSP-119).
The association between IgG (especially IgG3) responses to
block 2 and a significantly reduced risk of clinical disease is
important evidence that the block 2 region of MSP-1 is a
significant target of protective immune responses to P. falcipa-
rum. Biases to either IgG1 or IgG3 have been observed in
human responses to several defined protein antigens of P.
falciparum. Similar to the IgG3 bias of responses to block 2, the
main response to another merozoite surface protein (MSP-2)
of P. falciparum is of the IgG3 subclass (33, 39). IgG3 antibod-
ies are short-lived (half-life, 7 days), and thus require contin-
ued production to persist at levels that would have immediate
protective effects. The presence of IgG3 block 2-specific anti-
body before malaria transmission indicates either that antigen
(or parasitemia) persists in antibody-positive individuals or
that, in the absence of antigenic stimulation, block 2-specific B
cells persist at sufficiently high frequency to confer a protective
effect for prolonged periods. The general association between
the presence of cytophilic IgG subclasses, namely IgG1 and
IgG3, and protection against malaria has been shown by others
(3, 13). Such antibodies are proposed to play a role in protec-
tion through several mechanisms, including inhibition of par-
asite invasion by agglutination and/or opsonization of merozo-
ites, agglutination of parasites within erythrocytes, and
monocyte-mediated cellular inhibition. If there is sufficient
preexisting antibody to clear or inactivate the parasites rapidly,
it is possible that no further anti-block 2 response would ensue.
It might be difficult to envisage how low (but significantly
above background) levels of antibody could protect children
from clinical malaria episodes up to 17 months later. We sug-
gest, however, that even low levels of preexisting antibody
(where parasite antigen is in excess) would enhance antigen
presentation, leading to rapid secondary responses able to con-
trol liver and/or blood merozoites after new P. falciparum in-
fections. From the presented survival analysis, the association
between anti-block 2 antibodies and protection from malaria
over this long survey period remains statistically significant,
even though antibodies to block 2 may decay to levels not
immediately functionally protective. That naturally acquired
protection is relatively short-lived does not preclude the pos-
sibility that any vaccine based on block 2 could induce antibody
responses that would have longer-lasting effects. Persistence of
antigen in depots (in the context of vaccination) might well
provide the stimulus for more efficient immune responses to
MSP-1 and/or the parasite itself.
It has been suggested that, in some individuals, responses to
block 2 antigens may become fixed to a few specific epitopes,
regardless of the parasite type infecting the host, and that this
may be due to “clonal imprinting” or “original antigenic sin”
(24). This immunoevasion hypothesis suggests that an individ-
ual’s B cell repertoire against block 2 might become selected
and fixed by a first or early exposure to a particular parasite
antigenic variant, thereby preventing the recognition of other
variants in subsequent infections (18, 30). Here, 18% of chil-
dren in the cohort produced IgG to more than one block 2
type, and numerous examples of changing specificities were
seen between the start and the end of the malaria transmission
season (Fig. 4). Thus, in this cohort at least, responses of
individuals have not been fixed to any particular MSP-1 block
2 type, and these data give no support to the hypothesis of
original antigenic sin for block 2. The more likely explanation
for the relatively low frequencies of antibodies to block 2 lies in
the combination of antigenic polymorphism of this region with
the short-lived production and short half-life of specific IgG3.
The recombinant antigens used here mimic the antigenic
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structure of the block 2 region of Pf MSP-1 (7), and the panel
of antigens used contains sufficient diversity in the two block 2
types that contain repetitive regions to detect the majority of
antibody responses directed to this region of MSP-1. While it
is possible that linear peptides may represent epitopes present
in the block 2 region of MSP-1, no immunogenicity studies
with these peptides have been reported which might determine
their usefulness in assessing immune responses in naturally
exposed human populations (24). It is not excluded that in
some individuals, variant-specific (rather than type-specific)
antibodies were present which were not detectable by the vari-
ants in our panel. Single-variant-specific responses do occur,
albeit at low frequencies. However, the high correlation of
“within type” recognition of block 2 variants (data not shown)
argues against a high frequency of narrowly specific antibody
recognition of single block 2 variants, rather than recognition
of most variants within a type (7). Antibodies to block 2 are
directed predominantly against epitopes that are shared within
a type rather than against variant-specific epitopes. The lower
frequency of block 2 repeat-specific IgG versus type-specific
IgG seen in our cohort (Table 1) argues that repetitive se-
quences in block 2 are not immunodominant in this antigen.
However, there are important epitopes within the repetitive
sequences that cross-react between variants within a type (29).
The sequence polymorphism in the K1 and MAD20 types of
block 2 looks initially quite extensive (26) but is created by no
more than four to five tripeptide motifs, present in variable
numbers and in a limited number of combinations (23).
This prospective cohort study in an area of stable but sea-
sonal malaria transmission, which has combined accurate mon-
itoring of clinical status with sensitive assays of antibodies to
block 2, has confirmed and extended the seroepidemiological
evidence in support of the protective role for antibodies to
MSP-1 block 2 in naturally exposed populations (11). IgG3
responses to block 2 are associated with protection from sub-
sequent clinical malaria episodes in Ghanaian children, as
shown by using our panel of immunologically well character-
ized recombinant antigens. The protective potential of immu-
nity to block 2 should now be verified directly through the
experimental immunization of primates.
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